Last reviewed · How we verify
NCT06552403
Effect of a Modified 5:2 Intermittent Fasting Diet on Population With Overweight or Obesity in China
NA trial testing A modified 5:2 intermittent fasting diet in Overweight or Obesity in 45 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | Zhejiang Provincial Tongde Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- A modified 5:2 intermittent fasting diet
Conditions studied
- Overweight or Obesity — all drugs for Overweight or Obesity →
Sponsor
Zhejiang Provincial Tongde Hospital
Who can join
18 and older, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to investigate the effects of the modified 5:2 IF dietary intervention on the Chinese population with overweight or obesity based on a self-controlled clinical trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of a modified 5:2 intermittent fasting diet on a population who were overweight or obese in China: a self-controlled clinical trial.
Wang X, Gao Q, Xun Y, Wang Y, et al · · 2026 · PMID 41694464 · DOI 10.4162/nrp.2026.20.1.62
Verify or expand the search:
- PubMed search for NCT06552403
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight or Obesity
Currently open trials in the same condition.
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07431086 — Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US · Phase 2 · recruiting
- NCT07294235 — A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants · Phase 1 · recruiting
- NCT07224399 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multi · Phase 1 · recruiting
- NCT07170319 — A Study of IBI3032 in Chinese Participants With Overweight or Obesity · Phase 1 · active not recruiting
Other Zhejiang Provincial Tongde Hospital trials
Trials by the same sponsor.
- NCT06898476 — Silkworm Pupa Powder Improves Dementia. · NA · recruiting
- NCT06336993 — Evaluation of Clinical Efficacy of Herbal Compound in the Treatment of NSLBP · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06552403 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Provincial Tongde Hospital
- Last refreshed: 14 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06552403.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing